Challenges in treatment of RRMM
Fredrik Schjesvold, MD, PhD
Oslo Myeloma Center, Hematologist,Department of Hematology, Norway
Module 1: Optimizing treatment sequencing in RRMM
Accredited for 1 CME point
Module 2: Treating challenging RRMM patient subgroups
Accredited for 1 CME point
Module 3: Treatment implications and quality of life
Accredited for 1 CME point
Scientific Expert Panel
Inger Nijhof, MD, PhD
Hematologist,
St. Antonius Hospital,
Department of Internal Medicine,
The Netherlands
Fredrik Schjesvold, MD, PhD
Hematologist,
Oslo Myeloma Center,
Department of Hematology,
Norway
Isabelle Vande Broek, MD, PhD
Hematologist,
Vitaz, Sint-Niklaas,
Department of Oncology & Hematology,
Belgium
Agoston Gyula Szabo , MD
Hematologist,
Righospitalet Copenhagen,
Department of Hematology,
Denmark
Ville Varmavuo, MD, PhD
Chief Medical Officer in Education,
Kotka,
Internal Medicine,
Finland
Prof. Xavier Leleu, MD, PhD
Hematologist,
Academic Hospital of Poitiers,
France
Valdas Peceliunas, MD
Hematologist,
Vilnius University Hospital Santaros Klinikos,
Department of Hematology,
Lithuania
Accreditation
Accreditation for this e-learning has been granted for 1 point per module by:
European Accreditation Council for Continuing Medical Education (EACCME)
Obtain CME points
To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.
Clinical cases
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.